Key facts
- ENYO Pharma’s last known valuation is $92.9M (Dec 2020).
- It has raised $121.7M; the latest was Later Stage VC ($36.3M) in Jun 2025.
- Notable investors include Bpifrance, La French Tech, OrbiMed, Sofinnova Partners, Morningside Group — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for ENYO Pharma
- ·The full record, as it builds
Funding rounds
No funding rounds for ENYO Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ENYO Pharma
Operator of a clinical-stage biotechnology company intended to develop drug candidates by mimicking virus strategies to modulate host cellular functions. The company provides small molecule therapeutics based on fibrinolytic and anti-inflammatory properties, in various areas with unmet medical needs, as well as offers a drug discovery engine, enabling healthcare professionals to access therapeutics to treat rare kidney disease, Alport syndrome, and chronic liver diseases.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2014
- Employees
- 40
- Website
- enyopharma.com/
- Ownership
- Privately Held (backing)
ENYO Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ENYO Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ENYO Pharma in its N-PORT filings yet. We sweep new filings monthly.